Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AXGN

Axogen Inc

Dec 13 • 04:00PM ET

14.16

Dollar change -0.25
Percentage change -1.73	%

Healthcare • Medical Devices • USA • NASD

Peers: IART BAX SYK ZBH MDT JNJ GMED EW PODD HOLX

| Held by: VTI IWM VXF IWO DWAS IHI SCHA VTWO FESM DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.33	Insider Own	5.69%	Shs Outstand	44.00M	Perf Week	-5.03%
Market Cap	612.35M	Forward P/E	44.72	EPS next Y	0.32	Insider Trans	0.00%	Shs Float	41.50M	Perf Month	12.92%
Income	-14.31M	PEG	-	EPS next Q	0.03	Inst Own	83.84%	Short Float	2.62%	Perf Quarter	-0.91%
Sales	180.86M	P/S	3.39	EPS this Y	145.10%	Inst Trans	1.20%	Short Ratio	2.95	Perf Half Y	85.34%
Book/sh	2.26	P/B	6.27	EPS next Y	313.04%	ROA	-7.40%	Short Interest	1.09M	Perf Year	82.47%
Cash/sh	0.71	P/C	20.06	EPS next 5Y	-	ROE	-14.51%	52W Range	5.55 - 15.90	Perf YTD	107.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	3.44%	ROI	-8.60%	52W High	-10.94%	Beta	1.06
Dividend TTM	-	Quick Ratio	2.47	Sales past 5Y	13.87%	Gross Margin	76.40%	52W Low	155.14%	ATR (14)	0.62
Dividend Ex-Date	Jan 27, 2010	Current Ratio	3.74	EPS Y/Y TTM	39.37%	Oper. Margin	-4.70%	RSI (14)	51.14	Volatility	3.83% 3.80%
Employees	428	Debt/Eq	0.69	Sales Y/Y TTM	18.79%	Profit Margin	-7.91%	Recom	1.14	Target Price	18.57
Option/Short	Yes / Yes	LT Debt/Eq	0.67	EPS Q/Q	55.47%	Payout	-	Rel Volume	0.55	Prev Close	14.41
Sales Surprise	3.35%	EPS Surprise	1066.67%	Sales Q/Q	17.86%	Earnings	Nov 07 BMO	Avg Volume	368.54K	Price	14.16
SMA20	1.53%	SMA50	2.53%	SMA200	39.02%	Trades		Volume	202,875	Change	-1.73%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-24	Initiated	Raymond James	Outperform	$13
Nov-11-22	Resumed	Jefferies	Buy	$15
May-09-22	Upgrade	Canaccord Genuity	Hold → Buy	$10 → $15
Mar-11-22	Resumed	Cantor Fitzgerald	Overweight	$21
Oct-23-20	Initiated	Guggenheim	Buy	$24
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$16
May-07-20	Downgrade	Canaccord Genuity	Buy → Hold	$12
Apr-02-20	Downgrade	BTIG Research	Buy → Neutral
Aug-07-19	Downgrade	William Blair	Outperform → Mkt Perform
Jul-12-19	Initiated	Canaccord Genuity	Buy	$32
Mar-02-18	Reiterated	Lake Street	Buy	$26 → $38
Jan-05-18	Resumed	Cantor Fitzgerald	Overweight
Nov-30-17	Initiated	Jefferies	Buy	$35
Nov-21-17	Reiterated	Lake Street	Buy	$22 → $26
Jul-31-17	Initiated	Leerink Partners	Outperform	$22
Jun-30-17	Initiated	Cantor Fitzgerald	Overweight	$18
Mar-06-17	Initiated	ROTH Capital	Buy	$14.50
Nov-22-16	Upgrade	Lake Street	Hold → Buy	$9 → $11
Nov-07-16	Reiterated	Wedbush	Outperform	$10 → $12
Nov-03-16	Downgrade	Lake Street	Buy → Hold	$9

Show Previous Ratings

Nov-28-24 12:00PM	All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy (Zacks)
Nov-25-24 09:55AM	How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18% (Zacks)
Nov-08-24 07:35AM	AxoGen Reports Strong Q3 2024 Revenue Growth (TipRanks)
02:08AM	Axogen Inc (AXGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
Nov-07-24 07:48AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance) -13.44%
07:00AM	Loading…
07:00AM	Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update (GlobeNewswire)
Oct-24-24 07:00AM	Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024 (GlobeNewswire)
Oct-14-24 07:21AM	AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Oct-09-24 05:30PM	Axogen Inc (AXGN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... (GuruFocus.com)
Sep-12-24 01:30AM	ArrowMark Colorado Holdings LLC Reduces Stake in Axogen Inc (GuruFocus.com)
Sep-06-24 07:00AM	Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft (GlobeNewswire)
Sep-04-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-03-24 07:00AM	Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-30-24 12:00PM	What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-23-24 09:55AM	Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High? (Zacks)
09:15AM	Loading…
Aug-19-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-13-24 04:18PM	CytoSorbents Appoints Peter J. Mariani Chief Financial Officer (GlobeNewswire)
Aug-09-24 12:56AM	Axogen names ex-Abbott exec Michael Dale as CEO (MedTech Dive)
Aug-08-24 08:20AM	AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates (Zacks) +35.10%
07:19AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Announces New Leadership Appointments (GlobeNewswire)
07:00AM	Axogen, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 10:01AM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -7.06%
Jul-23-24 07:00AM	Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 (GlobeNewswire)
Jul-12-24 08:37AM	AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock? (Zacks)
Jul-01-24 07:00AM	Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.49%
Jun-25-24 12:52PM	AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection (Zacks)
Jun-24-24 07:00AM	Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix (GlobeNewswire)
Jun-12-24 04:56AM	Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength? (Zacks) +9.21%
May-28-24 04:30PM	Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia (GlobeNewswire) +5.90%
12:29PM	Loading…
May-17-24 12:29PM	AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft (Zacks)
May-16-24 02:56PM	AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft (MT Newswires)
07:00AM	Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft (GlobeNewswire)
May-14-24 07:00AM	Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference (GlobeNewswire)
May-06-24 10:31AM	AxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 03:02AM	Axogen Inc (AXGN) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
May-02-24 11:57AM	AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -10.37%
08:15AM	AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:14AM	AxoGen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 04:50PM	Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix (GlobeNewswire)
Apr-16-24 07:00AM	Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 (GlobeNewswire)
Mar-08-24 11:55PM	Director Gregory Freitag Sells 25,000 Shares of Axogen Inc (AXGN) (GuruFocus.com)
Mar-06-24 08:20AM	AxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-05-24 09:27PM	Q4 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents) -15.11%
11:53AM	AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:38AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance)
07:31AM	Axogen Inc (AXGN) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full-Year 2023 (GuruFocus.com)
07:00AM	Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)
Feb-28-24 08:50AM	AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Feb-26-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Feb-13-24 04:30PM	Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024 (GlobeNewswire)
Feb-12-24 08:50AM	Here's Why Momentum in AxoGen (AXGN) Should Keep going (Zacks)
Feb-06-24 09:40AM	Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-02-24 04:15PM	Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-26-24 08:50AM	Here's What Could Help AxoGen (AXGN) Maintain Its Recent Price Strength (Zacks)
Jan-18-24 05:00PM	Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap (GlobeNewswire) +7.86%
Jan-04-24 04:45PM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023 (GlobeNewswire) +26.67%
04:40PM	Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025 (GlobeNewswire)
04:35PM	Axogen Announces Promotions on Research and Development Team (GlobeNewswire)
Dec-26-23 04:15PM	Axogen, Inc. Appoints Kathy Weiler to its Board of Directors (GlobeNewswire)
Dec-06-23 07:00AM	Axogen Announces Transition of Finance Team Leadership (GlobeNewswire) +5.19%
Dec-01-23 05:00PM	Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.04%
Nov-20-23 07:00AM	Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-08-23 09:41AM	AxoGen, Inc. (NASDAQ:AXGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 11:01PM	Q3 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents) +36.90%
08:04AM	Axogen Inc (AXGN) Reports 12% Revenue Growth in Q3 2023 (GuruFocus.com)
07:15AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports 2023 Third Quarter Financial Results (GlobeNewswire)
Nov-02-23 10:00AM	Dynatronics Corporation (DYNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) +5.26%
Oct-31-23 10:01AM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-18-23 07:00AM	Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023 (GlobeNewswire)
Oct-16-23 10:23AM	Wayfair upgraded, JD.com downgraded: Wall Street's top analyst calls (The Fly) +5.28%
Sep-28-23 08:21AM	AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last? (Zacks)
Sep-05-23 07:00AM	Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector (GlobeNewswire)
Aug-31-23 07:00AM	Axogen to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-21-23 07:00AM	Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio (GlobeNewswire)
Aug-10-23 03:03PM	ArrowMark Colorado Holdings LLC Boosts Stake in Axogen Inc (GuruFocus.com) -6.51%
12:05PM	AxoGen, Inc. (NASDAQ:AXGN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-08-23 10:59AM	The past five years for AxoGen (NASDAQ:AXGN) investors has not been profitable (Simply Wall St.) -19.44%
05:57AM	Q2 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 05:25PM	AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:18PM	AxoGen: Q2 Earnings Snapshot (AP Finance)
04:01PM	Axogen, Inc. Reports 2023 Second Quarter Financial Results (GlobeNewswire)
Aug-03-23 05:55PM	Artivion (AORT) Q2 Earnings and Revenues Top Estimates (Zacks)
Jul-27-23 07:00AM	Axogen to Participate at Canaccord Genuitys 43rd Annual Growth Conference (GlobeNewswire) -6.83%
Jul-26-23 07:00AM	Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023 (GlobeNewswire)
Jun-10-23 10:42AM	With 71% ownership, AxoGen, Inc. (NASDAQ:AXGN) boasts of strong institutional backing (Simply Wall St.)
Jun-09-23 09:55AM	Wall Street Analysts Think AxoGen (AXGN) Could Surge 69.62%: Read This Before Placing a Bet (Zacks)
May-24-23 07:00AM	Axogen to Participate at Jefferies Healthcare Conference (GlobeNewswire)
May-12-23 07:00AM	Axogen to Participate at JMP Securities Life Sciences Conference (GlobeNewswire)
May-09-23 08:35AM	AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:34AM	AxoGen: Q1 Earnings Snapshot (AP Finance)
07:00AM	Axogen, Inc. Reports 2023 First Quarter Financial Results (GlobeNewswire)
Apr-18-23 04:05PM	Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023 (GlobeNewswire)
07:25AM	Even With A 26% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely (Simply Wall St.)
Mar-17-23 04:31AM	AxoGen, Inc. (NASDAQ:AXGN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-16-23 06:30AM	AxoGen Full Year 2022 Earnings: EPS Beats Expectations (Simply Wall St.)
Mar-14-23 11:23PM	Q4 2022 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents) +11.95%
07:00AM	Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zaderej Karen L.	SENIOR ADVISOR	Nov 07 '24	Proposed Sale	12.71	70,000	890,000		Nov 07 10:52 AM
Zaderej Karen L.	SENIOR ADVISOR	Sep 05 '24	Proposed Sale	13.00	150,000	1,950,000		Sep 05 04:33 PM
JOHNSON JOHN	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	29,016	Sep 04 09:13 PM
NEELS GUIDO J	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	90,816	Sep 04 09:11 PM
Levine Alan M	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	40,816	Sep 04 08:58 PM
Burke William P. Mr.	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	28,557	Sep 04 08:52 PM
THOMAS PAUL	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	32,052	Sep 04 08:33 PM
TYNDALL JOSEPH A.	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	22,557	Sep 04 07:52 PM
Wendell Amy McBride	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	102,899	Sep 04 05:18 PM
Donovan Michael Patrick	Officer	Aug 21 '24	Proposed Sale	12.42	28,003	347,810		Aug 21 04:31 PM
GREG FREITAG	Director	Aug 13 '24	Proposed Sale	11.17	15,000	167,520		Aug 13 05:00 PM
Zaderej Karen L.	SENIOR ADVISOR	Aug 12 '24	Proposed Sale	10.00	200,000	2,000,000		Aug 12 10:59 AM
Freitag Gregory Gene	Director	Jun 04 '24	Option Exercise	0.00	11,904	0	283,498	Jun 06 04:49 PM
Zaderej Karen L.	CEO	Mar 16 '24	Option Exercise	0.00	110,322	0	1,157,593	Mar 25 09:43 PM
Zaderej Karen L.	CEO	Mar 21 '24	Sale	7.68	39,280	301,670	1,124,565	Mar 25 09:43 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 16 '24	Option Exercise	0.00	18,675	0	180,615	Mar 25 09:40 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 21 '24	Sale	7.68	4,578	35,159	165,661	Mar 25 09:40 PM
Scopelianos Angelo	Chief R&D Officer	Mar 21 '24	Option Exercise	0.00	2,500	0	58,604	Mar 25 09:37 PM
Scopelianos Angelo	Chief R&D Officer	Mar 16 '24	Option Exercise	0.00	25,406	0	58,250	Mar 25 09:37 PM
Scopelianos Angelo	Chief R&D Officer	Mar 21 '24	Sale	7.68	6,881	52,846	52,999	Mar 25 09:37 PM
Donovan Michael Patrick	VP Operations	Mar 16 '24	Option Exercise	0.00	24,575	0	58,846	Mar 25 09:22 PM
Donovan Michael Patrick	VP Operations	Mar 21 '24	Sale	7.68	6,033	46,333	37,992	Mar 25 09:22 PM
Donovan Michael Patrick	VP Operations	Mar 07 '24	Sale	8.81	36,310	319,891	35,708	Mar 08 05:33 PM
Freitag Gregory Gene	Director	Mar 07 '24	Sale	9.00	25,000	225,000	271,594	Mar 08 05:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AXGN

Axogen Inc

Upgrade your FINVIZ experience